Zobrazeno 1 - 10
of 237
pro vyhledávání: '"I. Lancranjan"'
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 80:3267-3272
Octreotide (Sandostatin) is a synthetic analog of somatostatin, an endogenous GH inhibitory peptide that has been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly. When given sc in divided daily doses, it lowers serum GH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fabc35185496f92ea58f861423e93b6
https://doi.org/10.1210/jcem.80.11.7593436
https://doi.org/10.1210/jcem.80.11.7593436
Autor:
A, Colao, D, Ferone, P, Marzullo, P, Cappabianca, S, Cirillo, V, Boerlin, I, Lancranjan, G, Lombardi
The effects of a 12- to 24-month treatment with depot long-acting octreotide (OCT-LAR) on hormone profile, tumor mass, and clinical symptoms were reported in 36 patients with active acromegaly [GH, 34.2 +/- 5.6 microg/L; insulin-like growth factor I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f33a9585c9266fbf4e30be616517eb41
http://hdl.handle.net/11588/133968
http://hdl.handle.net/11588/133968
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 76:484-488
The efficacy and tolerability of a long term treatment (21-53 months; mean, 36) with a new injectable form of bromocriptine (Parlodel LAR, Sandoz) was assessed in 13 patients (9 males and 4 females, aged 14-68 yr) with macroprolactinoma. Parlodel LAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2685824476b6e3fcc7fc22ac0caf5043
https://doi.org/10.1210/jcem.76.2.8432794
https://doi.org/10.1210/jcem.76.2.8432794
Autor:
Patrick Petrossians, P. Flandroy, R. Abs, T. Stadnik, M. De Longueville, Achille Stevenaert, Albert Beckers, I. Lancranjan
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 75:275-280
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b1d02a2af777af92a1ff75a35ec2f7
https://doi.org/10.1210/jcem.75.1.1619019
https://doi.org/10.1210/jcem.75.1.1619019
Publikováno v:
Journal of Controlled Release. 16:27-41
Parenteral depot systems such as implants and microspheres from biodegradable polyesters have shown deviations from an ideal infusion-like profile. Although the origins of this biphasic behavior are still being discussed controversially, it seems tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46def12ed60c6773275180c7d504d008
https://doi.org/10.1016/0168-3659(91)90028-c
https://doi.org/10.1016/0168-3659(91)90028-c
Autor:
M. B. J. G. Vosmar, I. Lancranjan, P. F. M. van der Heijden, L. A. Schellekens, Jan A.M. Kremer, Rune Rolland
Publikováno v:
BJOG: An International Journal of Obstetrics and Gynaecology. 97:527-532
Summary. Recently, long-acting injectable forms of bromocriptine have become available for the prevention of lactation. The first developed depot-form was very effective, but had the disadvantage of a slowly metabolized carrier. We investigated the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5b78c9c06bd5ad1d6fa4a18123e569
https://doi.org/10.1111/j.1471-0528.1990.tb02524.x
https://doi.org/10.1111/j.1471-0528.1990.tb02524.x
Publikováno v:
Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society Volume 13: 1991.
In this paper we present a method of lens extraction after Nd:YAG laser capsu- lonucleolysis in the eyes with high myopia The treatment begins few months before lens extraction by scleroplasty associa- ted with cryoprofilaxy or with Argon la- ser end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646ad928b620c8343d35b7004163b17d
https://doi.org/10.1109/iembs.1991.684633
https://doi.org/10.1109/iembs.1991.684633
Autor:
F. Sarnacchiaro, G. Schettini, E Caruso, G. Lombardi, Bartolomeo Merola, A. Colao, I. Lancranjan
The effectiveness and long-term tolerability of a new formulation of bromocriptine with slow gastrointestinal release (Parlodel SRO) has been evaluated on ten patients with macroprolactinoma, seven patients with microprolactinoma and five patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8dc808c17e2109269943869a16265f4
http://hdl.handle.net/11588/337373
http://hdl.handle.net/11588/337373
Autor:
Bartolomeo Merola, F. Sarnacchiaro, A. Colao, Gennaro Schettini, E Caruso, F Briganti, G. Lombardi, I. Lancranjan
Publikováno v:
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 5(4)
Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactinemia, in reducing both plasma prolactin levels and in restoring fertility and/or menses in most patients. In this study a comparison between the injec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef17ec5d5342596cc1614c6baca685be
https://pubmed.ncbi.nlm.nih.gov/1796748
https://pubmed.ncbi.nlm.nih.gov/1796748
Autor:
I, Lancranjan, A B, Atkinson
Publikováno v:
Pituitary. 1(2)
A European multicentre, open-label 12-month study with Sandostatin LAR administered intramuscularly at 4-week intervals was initiated in 151 acromegalics responsive to octreotide. All patients received 3 injections of the 20 mg dose, following which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9eba7f9aa9e7640e90c15ea79a13be15
https://pubmed.ncbi.nlm.nih.gov/11081188
https://pubmed.ncbi.nlm.nih.gov/11081188